Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.6100 (0.92%) ($6.6100 - $6.6100) on Thu. Jul. 8, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.57% (three month average) | RSI | 40 | Latest Price | $6.6100(0.92%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.3% a day on average for past five trading days. | Weekly Trend | HTBX declines -2.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(54%) ARKG(53%) ARKK(51%) IBUY(49%) IPO(47%) | Factors Impacting HTBX price | HTBX will decline at least -4.285% in a week (0% probabilities). VIXM(-32%) VXX(-28%) UUP(-14%) TLT(-11%) XLP(-10%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.285% (StdDev 8.57%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.14 | 5 Day Moving Average | $6.71(-1.49%) | 10 Day Moving Average | $6.84(-3.36%) | 20 Day Moving Average | $7.14(-7.42%) | To recent high | -38.5% | To recent low | 13.6% | Market Cap | $727m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |